Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
European marketing authorization application withdrawn for Revaproxyn
November 10th, 2005
Allos Therapeutics, Inc., (ALTH) has withdrawn its European Marketing Authorization Application (MAA) for its investigational radiation sensitizer Revaproxyn (efaproxiral, Efaproxyn in the United States) for use as an adjunct to whole brain radiation therapy (WBRT) for the treatment of patients with brain metastases originating from breast cancer. The company made this decision as a result of the Rapporteurs' Day 180 Joint Assessment Report, which concluded that the current data package was not sufficient to support approval. The MAA was based upon the results of the company's phase III REACH trial, which demonstrated a statistically significant survival benefit in...
Source: Women's Health Weekly (2005-11-10)
|
